Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» In a strategic switch, Sumitomo Dainippon bags rights to a PhIII diabetes drug from Poxel in $300M deal
In a strategic switch, Sumitomo Dainippon bags rights to a PhIII diabetes drug from Poxel in $300M deal
In a strategic switch, Sumitomo Dainippon bags rights to a PhIII diabetes drug from Poxel in $300M deal
Submitted by
admin
on October 30, 2017 - 11:05am
Source:
Endpoints
News Tags:
Sumitomo Dainippon
diabetes
clinical trials
imeglimin
Poxel
Headline:
In a strategic switch, Sumitomo Dainippon bags rights to a PhIII diabetes drug from Poxel in $300M deal
Do Not Allow Advertisers to Use My Personal information
